Lakefront Biotherapeutics NV (LKFT)

Market Cap	2.07B +1.5%
Revenue (ttm)	1.13B +259.4%
Net Income	681.64M
EPS	10.14
Shares Out	65.66M
PE Ratio	3.18
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	164,054
Open	32.42
Previous Close	32.33
Day's Range	32.06 - 32.76
52-Week Range	25.68 - 36.24
Beta	0.06
Analysts	Hold
Price Target	30.31 (-6.1%)
Earnings Date	Nov 11, 2026

About LKFT

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 196
• Stock Exchange: Nasdaq
• Ticker Symbol: LKFT
• Website: https://lakefrontbio.com

Financial Performance

In 2025, LKFT's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.

Financial numbers in EUR

Analyst Summary

According to 6 analysts, the average rating for LKFT stock is "Hold." The 12-month stock price target is $30.31, which is a decrease of -6.10% from the latest price.

Price Target

$30.31

(-6.10% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 31, 2026

Data Sources Report a data error